Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: A meta-analysis of randomized clinical trials

Journal of Dermatological Treatment

Volumn 21, Issue 3, 2010, Pages 144-156

  Chen, Sheng Li ^a   Yan, Jun ^b   Wang, Feng Shan ^c  

^a Shandong Provincial Institute of Dermatology and Venereology   (China)

^b Jinan City Hospital for Skin Diseases Prevention and Treatment   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Atopic dermatitis; Children; Meta analysis; Pimecrolimus; Tacrolimus

Indexed keywords

PIMECROLIMUS; TACROLIMUS;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFANT; MAJOR CLINICAL STUDY; META ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN BURNING SENSATION; SKIN PRURITUS; SYSTEMATIC REVIEW;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENAL CORTEX HORMONES; CALCINEURIN; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 77951110311     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903401470     Document Type: Article

References (60)

1. Boguniewicz M, Leung DYM. Atopic dermatitis. J Allergy Clin Immunol. 2006;117:S475-S480.
2. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy. 2006;61:969-987. (Pubitemid 44024897)
3. Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol. 2001;107:519-525.
4. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4:1-191.
5. Gianni LM, Sulli MM. Topical tacrolimus in the treatment of atopic dermatitis. Ann Pharmacother. 2001;35:943-946.
6. Boguniewicz M, Schmid-Grendelmeier P, Leung DY. Atopic dermatitis. J Allergy Clin Immunol. 2006;118:40-43.
7. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361: 151-160. (Pubitemid 36092023)
8. Novak N, Bieber T, Leung DYM. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol. 2003;112:S128-S139.
9. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931-936.
10. Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol. 2003;28:549-553. (Pubitemid 37100564)
11. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: Meta-analysis of randomised controlled trials. BMJ. 2005;330:516.
12. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354: 1896-1900.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12. (Pubitemid 26120810)
14. Langley RG, Eichenfield LF, Lucky AW, Boguniewicz M, Barbier N, Cherill R. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol. 2008;25:301-307. (Pubitemid 351813950)
15. Neumann E, Amtage D, Bruckner-Tuderman L, Mockenhaupt M. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. J Dtsch Dermatol Ges. 2008;6:548-553.
16. Fowler J, Johnson A, Chen M, Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis. 2007;79:65-72.
17. Papp KA, Werfel T, Folster-Holst R, Ortonne JP, Potter PC, de Prost Y, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1%in infants and young children: A two-year study. J Am Acad Dermatol. 2005; 52:240-246.
18. Papp K, Staab D, Harper J, Potter P, Puig L, Ortonne JP, et al. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Int J Dermatol. 2004;43: 978-983.
19. Leo HL, Bender BG, Leung SB, Tran ZV, Leung DY. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol. 2004;114:691-693.
20. Barbier N, Paul C, Luger T, Allen R, De Prost Y, Papp K, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150:96-102.
21. Kang S, Paller A, Soter N, Satoi Y, Rico MJ, Hanifin JM. Safe treatment of head/neck AD with tacrolimus ointment. J Dermatolog Treat. 2003;14:86-94.
22. Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144:788-794. (Pubitemid 32374782)
23. Granlund H, Remitz A, Kyllonen H, Lauerma AI, Reitamo S. Treatment of lichenified atopic eczema with tacrolimus ointment. Acta Derm Venereol. 2001;81:314-315. (Pubitemid 32977124)
24. Liu LL, Wen WJ, Wang BX, Ma DL, Li HJ, Qi J, et al. Pimecrolimus cream 1% for the treatment of atopic dermatitis in Chinese children and adults: A multicenter randomized, double-blind, parallel-group, vehicle-controlled trial. Chin J Dermatol. 2007;40:34-37.
25. Jia H, Lin L, Gong JQ, Feng SY, Chen M, Cui PG. A randomized study of the safety and efficacy of pimecrolimus cream 1% in patients with atopic dermatitis. China J Lepr Skin Dis. 2006;22:215-216.
26. Wei MH, Yu BE, Chen LJ, Zhu M, Yang QP, Fu WW, et al. Efficacy and safety of tacrolimus ointment in treatment of atopic dermatitis of child and adult in 51 patients. Chin J New Drugs Clin Rem. 2005;24:704-708.
27. Wei MH, Yu BE, Chen LJ, Zhu M, Yang QP, Fu WW, et al. A clinical trial of 0.03% tacrolimus ointment in the treatment of atopic dermatitis in children and the investigation of DLQI. J Clin Dermatol. 2005;34:547-549.
28. Wei MH, Yu BE, Chen LJ, Zhu M, Yang QP, Fu WW, et al. Double blind randomized controlled clinical trial of tacrolimus ointment in the treatment of atopic dermatitis in children and adults. Chin J Clin Pharmacol. 2006;22: 11-14.
29. Gong JQ, Lin L, Yang XY, Jia H, Feng SY, Chen M, et al. Clinical trial of tacrolimus ointment for treatment of atopic dermatitis in children. Chin J Derm Venereol. 2005;19:21-23.
30. Ma DL, Wang BX, Li L, Yan Y, Sun QN, Li HC. Randomized controlled double blind clinical trial of tarcrolimus ointment in children with moderate to severe atopic dermatitis. Chin J Clin Pharmacol. 2005;21:243-247.
31. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol. 1998;102:637-644.
32. Drake L, PrendergastM,Maher R, Breneman D, Korman N, Satoi Y, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol. 2001;44: S65-S72.
33. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44:S47-S57.
34. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109:539-546. (Pubitemid 34234208)
35. Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: Results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150:554-562.
36. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51:515-525.
37. Liu LL, Dou X, Xie ZQ, Wang D, Zheng ZZ, Wei MH, et al. Efficacy and safety of tacrolimus ointment for the treatment of atopic dermatitis in Chinese children. Chin J Dermatol. 2005;38:608-611.
38. Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: Results from a randomized, double-blind, vehicle-controlled study. Pediatrics. 2005;116: e334-e342.
39. Paller AS, Lebwohl M, Fleischer AB Jr, Antaya R, Langley RG, Kirsner RS, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52:810-822.
40. Dou X, Liu LL, Xie ZQ, Chen LJ, Li L, Feng SY, et al. The impact of tacrolimus ointment on health-related quality of life of Chinese adult and pediatric patients with atopic dermatit. J Clin Dermatol. 2006;35:50-52.
41. Bieber T, Vick K, Fölster-Holst R, Belloni-Fortina A, Städtler G, Worm M, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62:184-189.
42. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495-504.
43. Whalley D, Huels J, McKenna SP, Van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics. 2002;110:1133-1136.
44. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the longterm management of atopic dermatitis in children. Pediatrics. 2002;110:e2.
45. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002; 110:277-284.
46. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142:155-162.
47. Breuer K, Braeutigam M, Kapp A, Werfel T. Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology. 2004;209:314-320.
48. Kaufmann R, Folster-Holst R, Hoger P, Thaci D, Loffler H, Staab D, et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol. 2004;114:1183-1188.
49. Staab D, Kaufmann R, Brautigam M, Wahn U; CASM981CDE04- Study Group. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: A multicenter, randomized trial. Pediatr Allergy Immunol. 2005;16:527-533.
50. Eichenfield LF, Lucky AW, Langley RG, Lynde C, Kaufmann R, Todd G, et al. Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: The effects of ethnic origin and baseline disease severity on treatment outcome. Int J Dermatol. 2005;44: 70-75.
51. Siegfried E, Korman N, Molina C, Kianifard F, Abrams K. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. J Dermatolog Treat. 2006;17:143-150.
52. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:S44-S47.
53. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144: S13-S14.
54. Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr. 2002;14:414-1418.
55. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131: 383-396.
56. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131: 406-416.
57. Seymour JL, Keswick BH, Hanifin JM, Jordan WP, Milligan MC. Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis. J Am Acad Dermatol. 1987;17:988-997.
58. Deng W, Guo ZP, Liu HJ. Topical tacrolimus for atopic dermatitis: A systematic review. Chin J Evid Based Med. 2004;4:293-299.
59. Iskedjian M, Piwko C, Shear NH, Langley RG, Einarson TR. Topical calcineurin inhibitors in the treatment of atopic dermatitis: A meta-analysis of current evidence. Am J Clin Dermatol. 2004;5:267-279.
60. Garside R, Stein K, Castelnuovo E, Pitt M, Ashcroft D, Dimmock P, et al. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: A systematic review and economic evaluation. Health Technol Assess. 2005;9:1-230.